CD19 and non-Hodgkin lymphoma: Glofitamab is also being tested in a number of combination trials for R/R and untreated B-cell NHL, such as in combination with chemotherapy as R-GemOx for R/R DLBCL or R-CHOP or R-CHP-polatuzumab vedotin in untreated DLBCL, in combination with monoclonal antibodies as atezolizumab or polatuzumab vedotin for R/R NHL, in combination with other BsAbs as the CD19 × CD3 RO7227166 for R/R NHL (Table 2).